Cultivation Process of Reishi-MRL™
Mycology Research Laboratories Ltd.´s Ganoderma lucidum powder contains both mycelium and primordia (young fruit body) cultivated into a biomass that is grown on a sterilised (autoclaved) substrate under ISO 22000:2018 standards in the EU.
This cultivation process ensures the powder complies with the EU regulation 1881/2006 for contamination of pesticides and heavy metals.
The cultivation system is proprietary, allowing for standardised production of Ganoderma lucidum.
Mycelium biomass of mushrooms offers a mixture of many co-operating and co-related healthful bioavailable ingredients prepared by nature itself – it is thus a truly pure natural product.
Mushrooms spend more than 90% of their life cycle in the mycelium. Since mushrooms cannot produce their own energy through photosynthesis, the mycelium must be able to actively obtain or produce extracellular compounds and metabolites that promote the longevity and vitality of the living mushroom. These properties lie behind the high enzymatic activity of the mycelium, which stays preserved in the carefully processed MRL products.
Manufacturing Process of Reishi-MRL™ in tablets presentations
The Ganoderma lucidum lucidum tablets are processed under FSSC 22000 standards in the Netherlands. This ensures that each tablet of 500 mg contains standardised Ganoderma lucidum product. The tablets are film coated to protect them from moisture, thus preserving the quality of the product and ensuring a long shelf life.
After passing quality control testing the tablets are released for use. The choice of additives used in manufacture renders these tablets suitable for Kosher or vegetarian use.
Manufacturing Process of Reishi-MRL™ in powder presentations
The Ganoderma lucidum biomass and all the powder presentations are produced and manufactured in accordance with both EU and UK organic standards.
Chemical and Biological Properties *
Each Tablet of Reishi-MRL contains
|Ganoderma lucidum - biomass powder||500 mg|
|Vegetable Magnesium Sterate|
Reishi-MRL - Enzyme Activity Per 750 mg Tablet
|Protein content||22.2 mg|
|Reducing sugars||24.0 mg|
|Protein-bound polysaccharide||69.5 mg|
|Glucose 2-oxidase activity||8.2 mU|
|Peroxidase activity||11.2 mU|
|Laccase activity||451.5 mU|
|Glucoamylase / beta-glucansase activity||2.7 U|
|Protease activity||4.4 mU|
|Superoxide dismutase (SOD) activity||50.4 mU|
|Cytochrome P-450||0.66 nmoles|
|Cytochrome P-450 reductase||7.05 mU|
|Secondary metabolites (Thrombin inhibitors)||4.4%|